phase1 · 2024
MSC in chronic kidney disease: early studies
Focused on safety and eGFR decline in small numbers of participants; no evidence of nephron regeneration.
ClinicalTrials.govTreatment example
Care journey example: chronic kidney disease
Preparation and screening steps for people with chronic kidney disease who are interested in stem cell research.
In short
Blood pressure, diabetes and proteinuria control plus kidney-protective medicines remain the core of care. Stem cell research in chronic kidney disease is mostly early-stage and safety-focused; restored kidney function is not established.
Step by step
Timings are a general example and may change with documents and clinical judgement.
- 01
Send your question and basic information
Day 1Complete the information-consultation form with your symptoms, how long you have had them, current medicines and previous treatments. The EHL Thailand information team replies in your dashboard. This step is educational information, not a diagnosis.
Who is involved: You + EHL Thailand information team
- 02
Collect your medical documents
Week 1–2Prepare discharge/treatment summaries, blood results, X-ray or MRI images and your medicine list. The more complete the records, the more accurate the eligibility review. Documents are used only with your consent (PDPA).
Who is involved: You + your current treating doctor
- 03
Review the research evidence together
Week 2The team summarises that existing MSC studies in chronic kidney disease are small phase 1–2 trials, and EHL BIO's urine-derived stem cell and Klotho work is preclinical.
Who is involved: Information team + content review panel
- 04
Clinical eligibility screening
Week 3–4A nephrologist reviews eGFR, its slope, proteinuria, complications and any dialysis/transplant plan. People with rapidly declining function may not be suited to waiting on research.
Who is involved: The doctor or clinic responsible for care in Korea
- 05
Informed consent before deciding
Before travellingBefore deciding you should receive documents stating that the treatment is investigational and not registered in Thailand, the risks, the alternatives, the full costs, and what is still unknown. No outcome guarantee should ever be given.
Who is involved: You + the treating doctor
- 06
Treatment and follow-up
From treatment day to 12 monthseGFR, proteinuria, blood pressure and complications are followed at 1, 3, 6 and 12 months by a nephrologist in Thailand.
Who is involved: Treating doctor + your doctor in Thailand
Documents to prepare
- Latest blood panel: creatinine, eGFR, albumin, potassium
- Urinalysis and protein/creatinine ratio
- Diabetes and hypertension history with control values
- Full medicine list including herbal products and supplements
Questions to ask your doctor
- How fast is my eGFR changing?
- Which kidney-protective medicines should I be on?
- Would joining a study affect my dialysis or transplant plan?
- Do any medicines need to stop first, and what are the risks?
Limits you must know
- Stem cell treatment for these conditions remains investigational; it is not standard care.
- EHL Thailand is an information and consultation channel, not a clinic, and does not diagnose or prescribe.
- EHL BIO pipeline cell products have no published Thai registration status.
- The timings shown are a general example and may change with documents, extra tests and clinical judgement.
Related disease page
Chronic Kidney Disease
Progressive loss of kidney function, commonly linked to diabetes and hypertension.
Research cited in this journey
review · 2026
EHL BIO patents and research papers
EHL BIO publishes a list of patents and research papers in the R&D section of its corporate website. Readers should verify the current list at the source before citing.
EHL BIO — Patents and Research Papersphase1 · 2023
KDSTEM Inj.: Phase 1 trial in chronic kidney disease (hospital information)
The hospital's affiliated research centre states IND approval and Phase 1 initiation in 2023, with selection for the KFRM programme in 2022 and 2024. A Phase 1 trial targets safety, not proof of efficacy.
EHL BIO (research page)Experts involved
Profiles show only details checkable against public sources.
EHL BIO Stem Cell Research Institute
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentEHL Thailand Research Desk
Reviews articles, research summaries and clinical trial status
Careful reading of study results, including sample size, trial phase and limitations
Experts behind this content
EHL Thailand Research Desk — Careful reading of study results, including sample size, trial phase and limitations
EHL BIO scientific information is compiled alongside public information from its research team and GMP centre. See the full expert panel
Frequently asked questions
Last updated 3 Sept 2026